Hubei Guangji Pharmaceutical Co Ltd (000952) — Net Asset Quality Index

Latest as of March 2026: 25.9%

Hubei Guangji Pharmaceutical Co Ltd (000952) has a Net Asset Quality Index of 25.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.29 Billion minus total liabilities of CN¥1.70 Billion yields net assets of CN¥593.68 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Hubei Guangji Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Quality Index

25.9%
Equity / Total Assets

Net Assets

CN¥593.68 Million
CNY

Total Assets

CN¥2.29 Billion
CNY

Total Liabilities

CN¥1.70 Billion
CNY

Hubei Guangji Pharmaceutical Co Ltd Net Asset Quality Index Over Time (1996–2025)

This chart shows how Hubei Guangji Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 30 annual periods from 1996 to 2025. As of March 2026, the index stands at 25.9%, representing net assets of CN¥593.68 Million against total assets of CN¥2.29 Billion CNY. Explore Hubei Guangji Pharmaceutical Co Ltd operating cash flow efficiency to assess how effectively this company generates cash.

Annual Net Asset Quality Index for Hubei Guangji Pharmaceutical Co Ltd (1996–2025)

The table below presents the year-by-year Net Asset Quality Index for Hubei Guangji Pharmaceutical Co Ltd from 1996 to 2025, covering 30 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Hubei Guangji Pharmaceutical Co Ltd market capitalisation.

Year Quality Index Net Assets (CNY) Total Assets Total Liabilities Change (pp)
2025 27.1% CN¥626.85 Million CN¥2.31 Billion CN¥1.69 Billion ▼ -11.4 pp
2024 38.5% CN¥1.08 Billion CN¥2.79 Billion CN¥1.72 Billion ▼ -7.4 pp
2023 46.0% CN¥1.39 Billion CN¥3.03 Billion CN¥1.64 Billion ▼ -14.5 pp
2022 60.4% CN¥1.49 Billion CN¥2.47 Billion CN¥977.25 Million ▼ -10.4 pp
2021 70.8% CN¥1.45 Billion CN¥2.05 Billion CN¥598.09 Million ▲ +1.8 pp
2020 69.0% CN¥1.37 Billion CN¥1.98 Billion CN¥613.75 Million ▲ +14.4 pp
2019 54.6% CN¥964.30 Million CN¥1.77 Billion CN¥802.21 Million ▲ +2.6 pp
2018 52.0% CN¥880.96 Million CN¥1.69 Billion CN¥812.33 Million ▲ +5.4 pp
2017 46.6% CN¥765.24 Million CN¥1.64 Billion CN¥876.65 Million ▲ +6.3 pp
2016 40.3% CN¥659.18 Million CN¥1.63 Billion CN¥974.70 Million ▲ +8.6 pp
2015 31.7% CN¥513.86 Million CN¥1.62 Billion CN¥1.11 Billion ▼ -0.2 pp
2014 31.9% CN¥505.45 Million CN¥1.58 Billion CN¥1.08 Billion ▼ -15.4 pp
2013 47.4% CN¥735.04 Million CN¥1.55 Billion CN¥816.78 Million ▼ -1.5 pp
2012 48.8% CN¥760.05 Million CN¥1.56 Billion CN¥795.93 Million ▼ -8.5 pp
2011 57.3% CN¥863.60 Million CN¥1.51 Billion CN¥643.07 Million ▼ -3.3 pp
2010 60.6% CN¥839.35 Million CN¥1.38 Billion CN¥545.06 Million ▼ -2.0 pp
2009 62.7% CN¥816.91 Million CN¥1.30 Billion CN¥486.93 Million ▼ -4.6 pp
2008 67.2% CN¥811.28 Million CN¥1.21 Billion CN¥395.78 Million ▼ -0.2 pp
2007 67.4% CN¥673.00 Million CN¥998.76 Million CN¥325.76 Million ▲ +6.5 pp
2006 60.8% CN¥477.68 Million CN¥785.02 Million CN¥307.34 Million ▲ +0.6 pp
2005 60.3% CN¥531.76 Million CN¥882.44 Million CN¥350.68 Million ▲ +2.9 pp
2004 57.4% CN¥523.19 Million CN¥911.95 Million CN¥388.76 Million ▼ -2.0 pp
2003 59.4% CN¥514.56 Million CN¥866.94 Million CN¥352.38 Million ▼ -2.5 pp
2002 61.8% CN¥506.86 Million CN¥819.91 Million CN¥313.05 Million ▼ -2.1 pp
2001 63.9% CN¥486.87 Million CN¥761.83 Million CN¥274.96 Million ▼ -7.3 pp
2000 71.2% CN¥481.54 Million CN¥676.22 Million CN¥194.67 Million ▲ +2.0 pp
1999 69.3% CN¥449.30 Million CN¥648.78 Million CN¥199.49 Million ▲ +18.6 pp
1998 50.7% CN¥191.95 Million CN¥378.76 Million CN¥186.80 Million ▲ +0.8 pp
1997 49.9% CN¥166.21 Million CN¥333.05 Million CN¥166.84 Million ▼ -4.9 pp
1996 54.8% CN¥134.18 Million CN¥244.89 Million CN¥110.72 Million
pp = percentage points